RT @ebsummiteurope: Policy Officer Lilia Luchianov from @EU_Health at the #HealthSummitEU2023: “Access, affordability and availability were the main homework for us when we first started drafting the #EUPharmaLegislation. At the same time, #innovation was something we had in mind throughout the… https://t.co/4KVSM5Zs5r https://t.co/EFLg6Qk2ef

🐦🔗: https://n.respublicae.eu/EU_Health/status/1666739499647348736

RT @ebsummiteurope: “It’s important that we bear in mind two core elements of the #EUPharmaLegislation: a) access and affordability, and b) innovation” - @EU_Health DG @SandraGallina at #HealthSummitEU2023 https://t.co/6tsg2WwS70

🐦🔗: https://n.respublicae.eu/EU_Health/status/1666719950168268801

RT @medicinesforEU: "The revision of the #EUPharmaLegislation will aim at boosting the potential of #GenericMedicines and #BiosimilarMedicines.
To ensure medicines availability for patients & reduce pharmaceutical expenditure, we need to invest more in this sector."
VP @MargSchinas at #MedsforEU22

🐦🔗: https://nitter.eu/ComissioEuropea/status/1542449955641720833